Could a heart drug be a new key to controlling high blood pressure?

NCT ID NCT06604897

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study looks at whether the medication Entresto (sacubitril/valsartan) helps Japanese patients with essential hypertension achieve blood pressure targets recommended by Japanese guidelines. Researchers will analyze electronic medical records from a large database, focusing on patients who started Entresto and tracking their blood pressure over several months. The goal is to see how many patients reach the desired systolic and diastolic blood pressure levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacubitril/valsartan (Entresto)
What this could lead to: If effective, this could support using Entresto as a treatment option for high blood pressure in Japanese patients.
What could go wrong: This is a retrospective database analysis, not a controlled trial, so results may be influenced by patient selection and missing data. It also focuses on a specific population, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL HYPERTENSION

Contacts and locations

Locations

Novartis

East Hanover, New Jersey, 07936, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.